Autologous Dendritic Vaccine Therapy in Metastatic Kidney Cancer: The ADAPT Trial and Beyond

Viraj A. Master, Robert G. Uzzo, Gennady Bratlavsky, Jose A. Karam

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Autologous dendritic-cell vaccine therapy combined with systemic therapy may be of benefit in patients with metastatic renal cell cancer undergoing cytoreductive nephrectomy according to results from the large ADAPT trial. Combined retrospective analysis and correlative immunology research revealed that patients receiving everolimus may have derived a greater benefit. The currently enrolling phase 2 CoImmune trial is designed to test this hypothesis in patients undergoing cytoreductive nephrectomy and systemic therapy.

Original languageEnglish
Pages (from-to)651-653
Number of pages3
JournalEuropean Urology Focus
Volume8
Issue number3
DOIs
StatePublished - May 2022

Keywords

  • Carcinoma, Renal Cell/drug therapy
  • Humans
  • Immunotherapy, Active
  • Kidney Neoplasms/drug therapy
  • Nephrectomy/methods
  • Retrospective Studies

Fingerprint

Dive into the research topics of 'Autologous Dendritic Vaccine Therapy in Metastatic Kidney Cancer: The ADAPT Trial and Beyond'. Together they form a unique fingerprint.

Cite this